Patent · US Active

Hepatocyte growth factor (HGF) binding antibody

US7659378B2 · kind B2 · utility

9Cited by

6References

7Claims

0Family size

Assignee

AVEO Pharmaceuticals, Inc. · US

Inventors

May Han · Brookline, US
S. Kirk Wright · Waltham, US
William M. Winston, Jr. · Marlborough, US
Lyne Breault · Brookline, US
Jie Lin · Dedham, US
Bijan Etemad-Gilbertson · Brookline, US
Christine Knuehl · Natick, US
Jeno Gyuris · Lincoln, US

Key dates

Filing date	Jun 1, 2007
Grant date	Feb 9, 2010
Priority date	—
Expiry date	Mar 14, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.